## FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	JVAL								
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 20(b) of the Investment Company Act of 1040

	or Section So(n) of the investment Company Act of 1940										
1. Name and Address of Reporting Person <sup>*</sup> Gillies Hunter	2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Aerovate Therapeutics, Inc.</u> [ AVTE ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner V Officer (give title Other (specify									
(Last) (First) (Middle)	3. Date of Earliest Transaction (Month/Day/Year) 12/20/2023	below) below)									
C/O AEROVATE THERAPEUTICS, INC.		CHIEF MEDICAL OFFICER									
930 WINTER STREET, SUITE M-500	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)									
(0)		X Form filed by One Reporting Person									
(Street) WALTHAM MA 02451		Form filed by More than One Reporting Person									
(City) (State) (Zip)	Rule 10b5-1(c) Transaction Indication										
	X Check this box to indicate that a transaction was made pursuant to satisfy the affirmative defense conditions of Rule 10b5-1(c). See In	a contract, instruction or written plan that is intended to struction 10.									
Table L. Non-Derivative Securities Acquired Disposed of or Beneficially Owned											

Table 1 - Non-Derivative Securities Acquired, Disposed 01, 01 Denencially Owned												
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)		
Common Stock	12/13/2023		M <sup>(1)</sup>		4,000	A	\$1.74	7,251	D			
Common Stock	12/20/2023		<b>S</b> <sup>(1)</sup>		4,000	D	\$19.5	3,251	D			

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (	ransaction of ode (Instr. Derivative		6. Date Exerc Expiration Da (Month/Day/)	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$1.74	12/20/2023		<b>M</b> <sup>(1)</sup>			2,924	(2)	09/03/2030	Common Stock	2,924	\$0	9,023	D		
Stock Option (Right to Buy)	\$1.74	12/20/2023		<b>M</b> <sup>(1)</sup>			1,076	(3)	09/03/2030	Common Stock	1,076	\$0	10,027	D		

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.

2. A total of 16,097 shares subject to an employee stock option were granted on September 4, 2020, with 10% of this option vested on May 1, 2020, 22.5% vested on May 1 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

3. A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

## <u>/s/ George A. Eldridge,</u> <u>Attorney-in-Fact</u>

<u>12/22/2023</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.